The Acquired Hemophilia Treatment market is expected to grow at a CAGR of 7.5 % to reach USD 26.8 Billion in 2031.
The global acquired hemophilia treatment market size is valued at USD 2,291.0 million in 2020. Increasing geriatric population and excellent drug pharmocodynamic and pharmacokinetic profile exhibited by immunomodulatory therapy are the key drivers pertaining to acquired hemophilia treatment market growth.
As per the research findings brought forward by the National Organization for Rare Disorders (NORD) (U.S.), acquired hemophilia is a rare autoimmune disorder in which the immune system mistakenly produce antibodies against clotting factor VIII. The disease is mostly prevalent in geriatric population with mortality rate of around 21%, if untreated. Promising results highlighted by immunomodulatory agents in the phase III clinical trials, with excellent therapeutic index will eventually increase its popularity as the first line drug therapy to drastically reduce inhibitors pertaining to clotting factor VIII in the human blood serum. However, the high cost associated with bypassing agents employed as hemostatic therapy hinders the market penetration of acquired hemophilia treatment market in the low and middle income countries
Acquired Hemophilia Treatment Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2031||$26.8 billion|
|Growth Rate||CAGR of 7.5 % during 2021-2031|
|Segment Covered||Therapy, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and Africa|
|Key Players Profiled||Baxter Healthcare Corporation, BioXcel Corporation, Genentech, Inc., GlaxoSmithkline, Plc., Ferring B.V., Mylan N.V., Novo Nordisk, Sanofi SA, Shire, Plc. and Teva Pharmaceutical Industries Ltd.|
Key Segments of the Global Acquired Hemophilia Treatment Market
Therapy Overview, (USD Million)
- Inhibitor Eradication Therapy
- Cytotoxic Agents
- Immunomodulatory Agents
- Hemostatic Therapy
- Recombinant Activated Factor VII/NovoSeven RT
- Recombinant Activated Factor VIII/Obizur
- Activated Prothrombin Complex Concentrate (aPCC)/FEIBA
Regional Overview, (USD Million)
- Rest of Europe
- Rest of Asia Pacific
- Rest of South America
Middle East and Africa
- Rest of Middle East and Africa
Reasons for the study
- The purpose of the study is to give an exhaustive outlook of the global acquired hemophilia treatment market
- To evaluate the impact of increased demand for acquired hemophilia treatment owing to large incidence of rare bleeding disorders. Major companies are therefore striving to deveop therapies and medicines in order to address the increasing demand.
What does the report include?
- The study on the global acquired hemophilia treatment market includes qualitative factors such as drivers, restraints, and opportunities
- The study covers a qualitative and quantitative analysis of the market segmented based on therapy. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments.
- The study covers the competitive landscape of existing/prospective players in the acquired hemophilia treatment industry and their strategic initiatives for product development.
Who should buy this report?
- This study is suitable for industry participants and stakeholders in the global acquired hemophilia treatment market
- The report will benefit executives of biopharmaceutical companies that are engaged in the development of medicines for the treatment of acquired hemophilia
- Managers within financial institutions looking to publish recent and forecasted statistics pertaining to acquired hemophilia treatment regimen
- Government organizations, regulatory authorities, policymakers, and organizations looking for investments in trends of the global acquired hemophilia treatment market
- Analysts, researchers, educators, strategy managers, and government institutions looking for insights into the market to determine future strategies
Frequently Asked Questions (FAQ) :
Acquired hemophilia prevalence is highly variable ranging from 0.045 per million in children to 14.7 per million adult population. It is an autoimmune disorder in which immunoglobulin G antibodies bind to the clotting factor VIII thereby drastically delaying the blood clotting time, which if not treated promptly may lead to fatal health complications. The mortality rate associate with acquired hemophilia is approximately 21%, caused due to incessant bleeding due to haemorrhage of internal organs. The diagnosis of acquired hemophilia is complicated owing to the overlapping symptoms with other autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, multiple sclerosis, allergic drug reactions etc.
Currently, physicians worldwide are adopting a two pronged strategy for treating acquired hemophilia patients, eradicating the inhibitor against clotting factor VIII and control bleeding. Methyl prednisolone is started immediately alone or in combination with cytotoxic agents such as cyclophosphamide, azathioprine, cyclosporine and other immunosuppressant to reduce the inhibitor titer volume to facilitate blood clotting. At present, monoclonal antibodies such as rituximab and emicizumab are being investigated in phase 3 clinical trials for its therapeutic efficacy in reducing the inhibitor titre volume in the blood plasma, based on the positive results it is anticipated to become the first line therapy for treating acquired hemophilia.
The most important aspect is to control bleeding in patients hospitalized for haemorrhage of vital organs. Desmopressin is usually prescribed in minor bleeding cases with low inhibitor titre in blood plasma. FEIBA having half-life of 4-7 hours and NovoSeven RT with half-life of 2 hours are the bypassing agents, which are the first line therapy adopted in patients suffering with severe bleeding with high inhibitor titre volume. Administration of 200 U/kg of Obizur has shown positive clinical outcomes with therapeutic levels of factor VIII restored in the blood plasma showcasing 86% success rate. Obizur is anticipated to show promising results in the near future for its therapeutic efficacy in treating acquired hemophilia.
Based on product, the global acquired hemophilia treatment market has been segmented into hemostatc therapy and inhibitor eradication therapy. Hemostatic therapy segment accumulated the maximum market share of over 50% in 2020 and is anticipated to retain its dominance through the forecast period. Hemostatic therapy is used for controlling the incessant bleeding due to hemorrhage and inhibitor eradication therapy is used to increase the blood serum levels of clotting factor VIII. Hemostatic therapy consists of desmopressin, NovoSeven RT, Obizur and FEIBA, which are primarily employed to stop the bleeding due to hemorrhage in patients suffering with acquired hemophilia.
Inhibitor eradication therapy segment is anticipated to be the fastest growing segment during the forecast period. Inhibitor eradication therapy comprises steroids such as methyl prednisolone which is used alone or in combination with cytotoxic agent such as cyclophosphamide or other immunosuppressant as the first line therapy to reduce the inhibitor titer in the blood serum against clotting factor VIII. Rituximab, Emicizumab are other immunomodulation agents which are used as second line therapy in patients showing resistance to combination therapy of steroid and cytotoxic agents.
North America dominated the global acquired hemophilia treatment market with approximately 36% share in 2020. Moreover, North America it is expected to retain its dominance through 2028. The major parameters responsible for its positive market growth are rising public health awareness resulting in early disease diagnosis and treatment for acquired hemophilia. Supportive reimbursement scenario for the medicines prescribed for the treatment of acquired hemophilia further fortifies the market growth in the region.
Europe is placed in the second position due to supportive regulatory environment provided by the European Medical Agency (EMA) by approving FastTrack designation for the drug discovery and development of medicines for treating acquired hemophilia. Asia Pacific is expected to grow at a lucrative CAGR primarily due to constant rise in elderly population suffering with acquired hemophilia.